Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1

Conditions

Somatostatinoma 1Pituitary Neoplasms 1Growth Hormone-Secreting Pituitary Adenoma 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1Adrenocortical Carcinoma 1

Interventions

Capecitabine 6Temozolomide 5Octreotide 4Everolimus 4Leucovorin 3vatalanib 2pentetreotide 2Trastuzumab 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Cisplatin 2Bortezomib 2Biological Therapy 2Bevacizumab 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pazopanib 1motesanib diphosphate 1gallium Ga 68 dotatate 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1aflibercept 1Thalidomide 1Streptozocin 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × antineoplaston AS 2-1 × Endocrine × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡